PROCEPT BioRobotics (PRCT) saw its stock price plummet by 5.63% during Wednesday's trading session, despite reporting better-than-expected second-quarter results. The medical device company, which specializes in robotics for minimally invasive surgery, faced a sell-off despite beating revenue estimates and raising its guidance for the year.

According to the company's financial report, PROCEPT BioRobotics achieved a revenue of $79.182 million in Q2, surpassing the IBES estimate of $76.4 million. This strong performance led the company to increase its 2025 revenue guidance, signaling confidence in its growth trajectory. However, investors seemed to focus on the continued losses, as the company reported a net loss of $19.578 million for the quarter.

The market's negative reaction to PROCEPT BioRobotics' earnings report suggests that investors may be concerned about the company's path to profitability. While the revenue growth is encouraging, the substantial net loss indicates that the company is still investing heavily in its operations and technology. As the medical robotics sector becomes increasingly competitive, shareholders appear to be weighing the company's strong top-line growth against its ongoing financial losses, leading to the sharp decline in stock price.